Pharminent

Gilead’s latest hep C combo approved in US

Vosevi is aimed at tough to treat patients.
The post Gilead’s latest hep C combo approved in US appeared first on Pharmaphorum. https://pharmaphorum.com/news/gileads-latest-hep-c-combo-approved-us/

Filed under: HCV

AbbVie’s 8-week hepatitis C drug granted early access in UK

AbbVie’s hepatitis C drug granted early access in UK
The post AbbVie’s 8-week hepatitis C drug granted early access in UK appeared first on Pharmaphorum. https://pharmaphorum.com/news/abbvies-hepatitis-c-drug-granted-early-access-uk/

Filed under: HCV

Japan Grants Priority Review to AbbVie’s Investigational Regimen for all Major HCV Genotypes

NewsThe Japanese MHLW designates priority review to certain medicines based on the clinical usefulness of the treatment and severity of the disease. Topics: Drug Pipeline http://www.dddmag.com/news/2017/03/japan-grants-priority-review-abbvies-investigational-regimen-all-major-hcv-genotypes

Filed under: HCV

Siemens Healthineers Gets FDA Premarket Approval for HCV Genotyping Test

https://www.genomeweb.com/business-news/siemens-healthineers-gets-fda-premarket-approval-hcv-genotyping-test

Filed under: HCV

EMA validates Validates Gilead’s MAA for chronic hepatitis C therapy

The European Medicines Agency (EMA) has validated and is assessing Gilead Sciences’ Marketing Authorization Application (MAA) for the investigational, once-daily, single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients. http://processandproduction.pharmaceutical-business-review.com/news/ema-validates-gileads-chronic-hepatitis-c-regimen-230117-5721592

Filed under: HCV

Sofosbuvir/velpatasvir improved patient-reported outcomes, knocked out HCV genotypes 1-6

AT THE LIVER MEETING 2016 BOSTON (FRONTLINE MEDICAL NEWS) – When given with ribavirin, a fixed-dose combination of sofosbuvir/velpatasvir (Epclusa) achieved a sustained viral response at 12 weeks (SVR-12) in 94% of decompensated cirrhotic patients with hepatitis C virus (HCV) genotypes 1-6 infection, according to Zobair M. Younossi, MD. Patients with and without cirrhosis also […] https://www.pm360online.com/sofosbuvirvelpatasvir-improved-patient-reported-outcomes-knocked-out-hcv-genotypes-1-6/

Filed under: HCV

Provisional NICE recommendation for Gilead’s Hepatitis C treatment

NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment of adult chronic hepatitis C genotype 1-6 patients in England and Wales.
This is the third sofosbuvir-based treatment to be recommended by NICE for treatment of the disease. Hepatitis C, if untreated, can cause serious liver damage and potentially life-threatening complications such as liver cancer.
read more http://www.pharmafile.com/news/509122/provisional-nice-recommendation-gilead-s-hepatitis-c-treatment

Filed under: HCV

J&J, Achillion aim for best-in-class with early HCV data

J&J, Achillion aim for best-in-class with early HCV data
slawrence
Fri, 09/09/2016 – 10:07

http://www.fiercebiotech.com/biotech/j-j-achillion-aim-for-best-class-early-hcv-data

Filed under: HCV

Highly curative hep C treatment safe, effective for drug users

Hep C patients being treated for opioid addiction achieved high rates of sustained virologic response after 12 weeks of therapy with elbasvir-grazoprevir compared to those taking placebo for 12 weeks before beginning the drug treatment. The patients in the elbasvir-grazoprevir group saw a reduced viral load, regardless of ongoing drug use. https://www.sciencedaily.com/releases/2016/08/160809095006.htm

Filed under: HCV

Gilead’s Hep C Revenue Slips As Competition Increases And Pricing Pressure Mounts

In other news, many children who have hepatitis C are not getting treatment because they don’t realize they have the disease, and inmates file a lawsuit alleging the Tennessee Department of Correction is denying them hep C treatment because the best available medication is too expensive. http://khn.org/?post_type=daily-breakout&p=643039

Filed under: HCV

US clears Gilead’s pan-genotypic hepatitis C therapy

Gilead’s Sovaldi-based combination therapy for hepatitis C has been cleared for use by the US Food and Drug Administration to treat all six types of the virus, potentially eliminating the need for genotype testing. http://www.pharmatimes.com/news/us_clears_gileads_pan-genotypic_hepatitis_c_therapy_1051536

Filed under: HCV

Gilead Sciences: A ‘Strong Uptick’ in New Hepatitis C Prescriptions

http://blogs.barrons.com/stockstowatchtoday/2016/06/17/gilead-sciences-a-strong-uptick-in-new-hepatitis-c-prescriptions/

Filed under: HCV

Gilead, Merck get CHMP backing for new hep C combinations

Approval of Epclusa and Zepatier will see the pan-genotypic drugs compete for market share.
http://www.pmlive.com/pharma_news/gilead,_merck_get_chmp_backing_for_new_hep_c_combinations_1032428

Filed under: HCV

EASL 2016: Merck’s ‘no patient left behind’ approach to hepatitis C

The company’s hep c med Zepatier faces an uphill battle as it competes against Gilead’s dominant treatments, leading Merck to look at typically untreated patient populations.  http://www.biopharmadive.com/news/easl-2016-mercks-no-patient-left-behind-approach-to-hepatitis-c-1/417612/

Filed under: HCV

AbbVie hepatitis C combo shows high cure rates

Presents promising new phase II data across all six major
HCV genotypes http://www.pmlive.com/pharma_news/abbvie_hepatitis_c_combo_shows_high_cure_rates_995113

Filed under: HCV

Merck patents on Hepatitis C treatment found valid in dispute with Gilead

http://finance.yahoo.com/news/merck-patents-hepatitis-c-treatment-212727558.html

Filed under: HCV

Gilead Sciences: Hepatitis C Prescriptions Slow, Market Share Holds Steady

http://blogs.barrons.com/stockstowatchtoday/2016/03/18/gilead-sciences-hepatitis-c-prescriptions-slow-market-share-holds-steady/

Filed under: HCV

Physicians Greet New HCV Drug Zepatier Cautiously

Lack of familiarity with the drug and its cost, as well as the availability of rival therapies, may help explain the quiet reception of elbasvir/grazoprevir. Medscape Medical News http://www.medscape.com/viewarticle/859600?src=rss

Filed under: HCV

FDA expands use of BMS’ hepatitis C drug

FDA expands use of BMS’ hepatitis C drug http://pharmatimes.com/Article/16-02-08/FDA_expands_use_of_BMS_hepatitis_C_drug.aspx

Filed under: HCV

Market Just Got More Crowded as Merck & Co.’s New Hepatitis C Drug Wins FDA Approval

http://www.biospace.com/news_story.aspx?StoryID=407061&full=1

Filed under: HCV

Categories